INTRODUCTION
============

Antiretroviral therapy for the treatment of human immunodeficiency virus (HIV) infection has improved and reduced HIV-associated morbidity and mortality \[[@R1]-[@R3]\]. Recently, integrase strand transfer inhibitors (INSTIs), as a new class of drugs, were developed \[[@R4]\]. In Japan, the first INSTI called raltegravir was approved for treatment of HIV infection in 2008 \[[@R5]\]. Several studies have reported that an antiretroviral regimen with INSTI has a high efficacy for maintaining viral suppression, and low short-term and long-term toxicities \[[@R6]-[@R10]\]. The guidelines for use of antiretroviral therapy in patients with HIV in the United States, Europe, and Japan include recommendations on switching to an antiretroviral regimen with an INSTI in the setting of viral suppression and viral failure \[[@R3], [@R5], [@R11]\]. However, the effect of this switching in clinical practice for patients with HIV on long-term antiretroviral therapy has not been sufficiently examined \[[@R3], [@R12]\].

Cohort studies are essential for providing information on clinical practices and actual long-term effects of antiretroviral treatments for patients with HIV \[[@R12], [@R13]\]. The Japan Cohort Study of HIV Patients Infected through Blood Products is one of these cohorts \[[@R14]-[@R16]\]. The participants in this cohort included many people with HIV infection by blood products in the 1980s. Most registrations were in the 1990s and the participants' follow-ups are almost complete.

This study aimed to determine the effect of switching to an antiretroviral regimen with an INSTI on HIV RNA levels and the cluster of differentiation four (CD4) cell count from 2007 to 2014. We used data from the Japan Cohort Study of HIV Patients Infected through Blood Products.

METHODS
=======

The Japan Cohort Study of HIV Patients Infected Through Blood Products
----------------------------------------------------------------------

In Japan, a research program for people with HIV infection by use of contaminated blood coagulation factor products has been carried out since the 1993 fiscal year with the support of the Ministry of Health, Labour and Welfare \[[@R14], [@R15]\]. This program is intended to help prevent these people from developing HIV-infected symptoms in daily living by providing health management expenses. For this program, participants are requested to submit reports filled out by their treatment physician on a quarterly basis. These reports include HIV RNA levels, CD4 cell count, and administered antiretroviral drugs. If participants are diagnosed with acquired immunodeficiency syndrome (AIDS), they are excluded from this program. The Japan Cohort Study of HIV Patients Infected through Blood Products, which was based on this program, was started at the same time. Details of the cohort study are described elsewhere \[[@R14]-[@R16]\].

Data Analysis
-------------

We selected a subset cohort from the Japan Cohort Study of HIV Patients Infected through Blood Products \[[@R16]\]. The cohort consisted of 564 male hemophiliac patients on April 1, 2007, who had been infected with HIV by blood products in the 1980s. Data that were used included HIV RNA levels, CD4 cell count, and administered antiretroviral drugs at the first quarter (from 1 April to 31 June) of the 2007 and 2014 fiscal years.

The changes in antiretroviral regimen use between 2007 and 2014 were examined. The antiretroviral regimen was classified into five categories as follows: no regimen; regimens including two nucleoside reverse transcriptase inhibitors and one or two protease inhibitors (two NRTIs + PI\[s\]); regimens including two NRTIs and one non-nucleoside reverse transcriptase inhibitor (two NRTIs + NNRTI); regimens including two NRTIs and one INSTI (two NRTIs + INSTI); and other regimens. The differences between HIV RNA levels in 2007 and 2014 and those between CD4 cell counts in 2007 and 2014 for the total participants and those with use of two NRTIs + INSTI were examined. Proportions of HIV RNA \<50 copies/mL were calculated and the differences were tested using the McNemar test. The median, and 25th and 75th percentiles of CD4 cell counts were calculated and the differences were tested using the sign test. Progression to AIDS or death was assumed as the highest level in HIV RNA and as the lowest level in CD4 cell count. All analyses were performed using the SAS statistical package, version 9.3 (SAS, Institute, Cary, NC, USA).

Ethical Considerations
----------------------

This study was approved in June 2015 by the Ethical Review Board for Clinical Studies of National Hospital Organization Osaka National Hospital, Osaka, Japan (No. 15026).

RESULTS
=======

The participants were 564 men aged between 23 and 71 years old (mean, 37.7 years old) at 1 April 2007. Of these, 79 progressed to AIDS or death by 31 June 2014. Table **[1](#T1){ref-type="table"}** shows the numbers of participants with antiretroviral regimen use in 2007 and 2014. The proportion of use of two NRTIs + INSTI dramatically increased from 0.0% to 41.0% over this time. Proportions of each use of no regimen, two NRTIs + PI(s), two NRTIs + NNRTI, and other regimens declined over this time. The numbers of participants with changes in regimen use from no regimen, two NRTIs + PI(s), two NRTIs + NNRTI, and other regimens to two NRTIs + INSTI were 50, 110, 36, and 34, respectively.

Table **[2](#T2){ref-type="table"}** and Fig. (**[1](#F1){ref-type="fig"}**) show proportions of HIV RNA levels \<50 copies/mL in 2007 and 2014. The proportion of HIV RNA levels \<50 copies/mL for a total of 548 participants (included 79 cases of progression to AIDS or death, but not 16 cases with missing data of HIV RNA levels) significantly increased from 63.3% in 2007 to 74.5% in 2014. The proportion of participants with a change to use of two NRTIs + INSTI significantly increased from 58.3% to 90.6% over this time. The proportion of participants with changes in antiretroviral therapy use from no regimen, two NRTIs + PI(s), two NRTIs + NNRTI, and other regimens to two NRTIs + INSTI significantly increased over this time.

Table **[3](#T3){ref-type="table"}** and Fig. (**[2](#F2){ref-type="fig"}**) show the median, and 25th and 75th percentiles of the CD4 cell count in 2007 and 2014. The median CD4 cell count for a total of 543 participants (included 79 cases of progression to AIDS or death, but not 21 cases with missing data of CD4 cell count) significantly increased from 388/μL to 437/μL over this time. The median CD4 cell count of participants with a change to use of two NRTIs + INSTI significantly increased from 380/μL to 438/μL over this time. The median CD4 cell count of participants with changes in antiretroviral regimen use from no regimen, two NRTIs + PI(s), two NRTIs + NNRTI, and other regimens to two NRTIs + INSTI increased. Additionally, the median CD4 cell count for those from two NRTIs + PI(s) to two NRTIs + INSTI significantly increased.

DISCUSSION
==========

The proportion of use of antiretroviral regimens with an INSTI in our participants dramatically increased from 0.0% to 41.0% between 2007 and 2014. The reason for not using these regimens in 2007 is that, the first INSTI (raltegravir) was approved for treatment of HIV infection in 2008 in Japan \[[@R5]\]. The increase in use of regimens between 2007 and 2014 was mainly caused by the recommendations for switching to antiretroviral regimens with INSTIs in the setting of viral suppression and viral failure in guidelines in the USA, Europe, and Japan \[[@R3], [@R5], [@R11]\]. Our participants included more than 80% of people alive on April 1, 2007 who were infected by blood products in the 1980s in Japan. Many of these participants had long-term antiretroviral treatment with several drugs \[[@R14]-[@R16]\]. The finding of a large increase in use of antiretroviral regimens with an INSTI in the present study showed that there was a large effect of INSTIs in clinical practice for Japanese patients with HIV on long-term antiretroviral treatment.

A large improvement in HIV RNA levels and CD4 cell count for patients with HIV and changes in use of antiretroviral regimens with INSTIs between 2007 and 2014 were observed in the present study. These results are consistent with findings by previous studies \[[@R6]-[@R10]\]. Our results also confirmed that switching to antiretroviral regimens with INSTIs in clinical practice would lead to favorable effects of HIV RNA levels and CD4 cell count. Our findings suggested that there was a large effect of INSTIs on clinical improvement in the whole population of patients with HIV under long-term antiretroviral treatment.

This study has some limitations and problems. We used data from the Japan Cohort Study of HIV Patients Infected through Blood Products \[[@R14], [@R15]\]. Our participants were Japanese male hemophiliac patients with HIV who were infected by blood products in the 1980s, but we did not include females. Most participants appeared to have some favorable factors for switching to antiretroviral therapy (e.g., long-term, routinely good medical care, sufficient monitoring of HIV RNA levels and CD4 cell count, and relatively complete adherence of antiretroviral therapy) \[[@R14]-[@R16]\]. The data that were used in this study were at only one time point in each of 2007 and 2014. Participants who changed from no treatment in 2007 to antiretroviral regimen use, including INSTIs in 2014, in our study would have had initiation of antiretroviral regimen use, including INSTIs for treatment-naive patients between 2007 and 2014. Additionally, there also would have been those who switched to antiretroviral regimens with INSTIs after initiation of an antiretroviral regimen without INSTIs between 2007 and 2014. We observed changes in antiretroviral regimen use between 2007 and 2014. Currently, antiretroviral regimens are being continually developed, research on these regimens is ongoing, and guidelines are constantly being updated \[[@R3], [@R5], [@R11]\]. In Japan, other INSTIs, such as elvitegravir and dolutegravir, were approved in 2013 and 2014, respectively \[[@R5]\]. The current antiretroviral regimens with INSTIs have a risk of viral failure because of drug-resistance, similar to other regimens \[[@R3]\]. Changes in antiretroviral regimen use will continue in the future \[[@R3]\]. We analyzed HIV RNA levels and CD4 cell count as effects of switching to an antiretroviral regimen with an INSTI. Evaluating effects of switching regimens requires observations of other variables, such as adverse events and quality of life \[[@R3], [@R12]\].

CONCLUSION
==========

We found a considerable effect of switching to antiretroviral regimens with INSTIs for Japanese patients with HIV who were infected by blood products. This finding suggests that this switch in clinical practice will lead to favorable effects.
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###### 

Number of participants with antiretroviral regimen use in 2007 and 2014.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                    **Antiretroviral regimen use in 2014**   **Progression to AIDS or**\   **Total (%)**                                                         
                                                                             **death**                                                                                           
  --------------------------------- ---------------------------------------- ----------------------------- --------------- -------- ------- ------- -------- --------- --------- --------
  **Antiretroviral regimen use**\   **No regimen**                           26                            13              11       50      2       0        12        114       (20.2)
  **in 2007**                                                                                                                                                                    

  **Two NRTIs**\                    1                                        81                            14              110      13      1       33       253       (44.9)    
  **+ PI(s)**                                                                                                                                                                    

  **Two NRTIs**\                    1                                        5                             46              36       3       2       16       109       (19.3)    
  **+ NNRTI**                                                                                                                                                                    

  **Two NRTIs**\                    0                                        0                             0               0        0       0       0        0         (0.0)     
  **+ INSTI**                                                                                                                                                                    

  **Other**\                        2                                        10                            3               34       16      1       12       78        (13.8)    
  **regimens**                                                                                                                                                                   

  **Unknown**                       1                                        1                             0               1        1       0       6        10        (1.8)     

  **Total**                         31                                       110                           74              231      35      4       79       564       (100.0)   

  **(%)**                           (5.5)                                    (19.5)                        (13.1)          (41.0)   (6.2)   (0.7)   (14.0)   (100.0)             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Two NRTIs + PI(s): regimens including two nucleoside reverse transcriptase inhibitors (NRTIs) and one or two protease inhibitors. Two NRTIs + NNRTI: regimens including two NRTIs and one non-nucleoside reverse transcriptase inhibitor. Two NRTIs + INSTI: regimens including two NRTIs and one integrase strand transfer inhibitor. Progression to AIDS or death was between 1 April 2007 and 31 June 2014.

###### 

Proportion of HIV RNA levels \<50 copies/mL in 2007 and 2014.

  **Antiretroviral regimen use**   **No.**             **Proportion of HIV RNA levels \<50 copies/mL (%)**   **P value**          
  -------------------------------- ------------------- ----------------------------------------------------- ------------- ------ -------
  Total                            Total               548                                                   63.3          74.5   0.000
  Total                            Two NRTIs + INSTI   223                                                   58.3          90.6   0.000
  No regimen                       Two NRTIs + INSTI   48                                                    6.3           89.6   0.000
  Two NRTIs + PI(s)                Two NRTIs + INSTI   105                                                   76.2          87.6   0.019
  Two NRTIs + NNRTI                Two NRTIs + INSTI   36                                                    75.0          97.2   0.027
  Other regimens                   Two NRTIs + INSTI   34                                                    58.8          94.1   0.002

Two NRTIs + PI(s): regimens including two nucleoside reverse transcriptase inhibitors (NRTIs) and one or two protease inhibitors. Two NRTIs + NNRTI: regimens including two NRTIs and one non-nucleoside reverse transcriptase inhibitor. Two NRTIs + INSTI: regimens including two NRTIs and one integrase strand transfer inhibitor. P value of McNemar test for differences between proportions of HIV RNA levels \<50 copies/mL in 2007 and 2014.

###### 

Median, and 25th and 75th percentiles of the CD4 cell count in 2007 and 2014.

  -----------------------------------------------------------------------------------------------------------------
  **Antiretroviral**\   **No.**      **CD4 cell count (/μL)**   **P value**                                 
  **regimen use**                                                                                           
  --------------------- ------------ -------------------------- ------------- ----- ----- ----- ----- ----- -------
  Total                 Total        543                        388           262   552   437   265   606   0.024

  Total                 Two NRTIs\   227                        380           264   539   438   318   630   0.000
                        + INSTI                                                                             

  No regimen            Two NRTIs\   49                         389           295   446   421   338   533   0.085
                        + INSTI                                                                             

  Two NRTIs\            Two NRTIs\   109                        381           259   582   460   307   642   0.007
  + PI(s)               + INSTI                                                                             

  Two NRTIs\            Two NRTIs\   35                         380           222   673   514   335   823   0.090
  + NNRTI               + INSTI                                                                             

  Other\                Two NRTIs\   34                         369           268   524   408   207   629   0.121
  regimens              + INSTI                                                                             
  -----------------------------------------------------------------------------------------------------------------

Two NRTIs + PI(s): regimens including two nucleoside reverse transcriptase inhibitors (NRTIs) and one or two protease inhibitors. Two NRTIs + NNRTI: regimens including two NRTIs and one non-nucleoside reverse transcriptase inhibitor. Two NRTIs + INSTI: regimens including two NRTIs and one integrase strand transfer inhibitor. P value of the sign test for differences between CD4 cell counts in 2007 and 2014.
